The U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for Zoetis' (NYSE: ZTS) Simparica TRIO for the treatment of New World screwworm infestations in dogs and puppies, according to a press release statement.

Simparica TRIO, which contains sarolaner, moxidectin, and pyrantel, was originally approved by the FDA in 2020 for heartworm, flea, and tick-related indications. The new EUA does not authorize the product for prevention of New World screwworm, only for treatment.

The FDA stated it concluded that the known and potential benefits of Simparica TRIO outweigh its known and potential risks when used as authorized for this indication.

New World screwworm has currently only been detected in specific areas of Texas and New Mexico, according to the U.S. Department of Agriculture. Dogs living in, traveling to, or returning from affected areas should be monitored for signs of infestation, including visible maggots or foul odors in wounds or body openings.

Acting FDA Commissioner Kyle Diamantas said the authorization gives veterinarians and pet owners additional treatment options "in the unlikely event animals under their care become infested."

Simparica TRIO is available by prescription only due to the potential for neurologic adverse reactions associated with sarolaner, an isoxazoline-class antiparasitic. Reported reactions include muscle tremors, loss of coordination, and seizures.